Your session is about to expire
← Back to Search
Procedure
Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension
N/A
Waitlist Available
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1,3,6,12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new treatment called venous sinus stenting for patients with Increased Intracranial Hypertension (IIH) who don't get better with standard treatments. The stent is a small tube placed in a brain vein to keep it open, which helps lower pressure inside the head. This can improve symptoms like headaches and vision problems. Venous sinus stenting has shown promising results in treating patients with idiopathic intracranial hypertension (IIH) who are refractory to medical treatment.
Eligible Conditions
- Pseudotumor cerebri
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1,3,6,12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1,3,6,12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Normalized CSF pressure post venous stenting
Secondary study objectives
Assess the long-term success of this treatment in terms of clinical recurrence rate and long-term patency of the sinus.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: NeurointerventionalExperimental Treatment1 Intervention
Stenting of the venous sinus is the neuro-interventional treatment that is being offered to patients with idiopathic intracranial hypertension that are refractory to medical management.
Find a Location
Who is running the clinical trial?
Ottawa Hospital Research InstituteLead Sponsor
576 Previous Clinical Trials
3,139,895 Total Patients Enrolled